Symbols / FBLG Stock $1.56 +2.63% FibroBiologics, Inc.
FBLG (Stock) Chart
About
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Stock Fundamentals
Scroll to Statements| Market Cap | 7.08M | Enterprise Value | 2.79M | Income | -18.65M | Sales | — | Book/sh | 1.85 | Cash/sh | 1.45 |
| Dividend Yield | — | Payout | 0.00% | Employees | 15 | IPO | — | P/E | — | Forward P/E | -0.41 |
| PEG | — | P/S | — | P/B | 0.84 | P/C | — | EV/EBITDA | -0.17 | EV/Sales | — |
| Quick Ratio | 2.78 | Current Ratio | 3.61 | Debt/Eq | 39.15 | LT Debt/Eq | — | EPS (ttm) | -8.40 | EPS next Y | -3.85 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-02-24 | ROA | -79.85% | ROE | -4.19% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.54M | Shs Float | 2.93M | Short Float | 6.56% |
| Short Ratio | 0.43 | Short Interest | — | 52W High | 26.54 | 52W Low | 1.03 | Beta | 1.10 | Avg Volume | 343.36K |
| Volume | 88.12K | Target Price | $19.00 | Recom | Buy | Prev Close | $1.52 | Price | $1.56 | Change | 2.63% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-16 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2026-03-26 | down | D. Boral Capital | Buy → Hold | — |
| 2026-03-12 | main | D. Boral Capital | Buy → Buy | $7 |
| 2026-02-26 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2026-02-25 | main | D. Boral Capital | Buy → Buy | $7 |
| 2026-01-06 | main | D. Boral Capital | Buy → Buy | $15 |
| 2026-01-02 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-11-20 | main | D. Boral Capital | Buy → Buy | $15 |
| 2025-11-05 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-11-03 | main | D. Boral Capital | Buy → Buy | $15 |
| 2025-09-12 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-09-10 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-08-05 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-08-04 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-07-29 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-07-09 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-06-17 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-05-15 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-04-09 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
- FibroBiologics clears Nasdaq hurdles, keeps trading under FBLG - Stock Titan Mon, 20 Apr 2026 20
- Stocks to watch after market on Wednesday: DRVN, EGO, FBLG - MSN hu, 23 Apr 2026 04
- $FBLG stock is up 22% today. Here's what we see in our data. - Quiver Quantitative Mon, 02 Mar 2026 08
- FibroBiologics (FBLG) asks shareholders to OK March warrant issuances, equity plan - Stock Titan Wed, 22 Apr 2026 20
- FibroBiologics Compliant with All Nasdaq Listing Requirements - Yahoo Finance Singapore Mon, 20 Apr 2026 20
- FibroBiologics (FBLG) Sees Price Target Increase Amid Strategic Changes - GuruFocus Fri, 17 Apr 2026 00
- Insider Purchase: Chief Financial Officer of $FBLG Buys 70,000 Shares - Quiver Quantitative ue, 03 Mar 2026 08
- FibroBiologics (Nasdaq: FBLG) clears listing issues but faces one-year monitor - Stock Titan Mon, 20 Apr 2026 20
- FibroBiologics clears Nasdaq compliance, meets $2.5M equity rule - MSN hu, 23 Apr 2026 09
- $FBLG stock is up 10% today. Here's what we see in our data. - Quiver Quantitative Wed, 31 Dec 2025 08
- Lower quorum set for FibroBiologics (NASDAQ: FBLG) meetings - Stock Titan Fri, 17 Apr 2026 20
- FibroBiologics to implement 1-for-20 reverse stock split to meet Nasdaq requirement - MSN Wed, 25 Mar 2026 20
- First batch of foot-ulcer therapy made for planned human trial - Stock Titan ue, 31 Mar 2026 07
- FibroBiologics, Inc. Announces Pricing of Public Offering for 2.27 Million Shares and Warrants | FBLG Stock News - Quiver Quantitative Wed, 01 Apr 2026 07
- Biotech FibroBiologics raises $3M, with warrants for $3M more - Stock Titan hu, 02 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
16.65
+21.20%
|
13.74
+54.54%
|
8.89
+98.99%
|
4.47
|
| Research And Development |
|
7.41
+64.45%
|
4.50
+90.20%
|
2.37
+106.45%
|
1.15
|
| Selling General And Administration |
|
9.24
+0.10%
|
9.23
+41.59%
|
6.52
+96.42%
|
3.32
|
| General And Administrative Expense |
|
9.24
+0.10%
|
9.23
+41.59%
|
6.52
+96.42%
|
3.32
|
| Other Gand A |
|
9.24
+0.10%
|
9.23
+41.59%
|
6.52
+96.42%
|
3.32
|
| Total Expenses |
|
16.65
+21.20%
|
13.74
+54.54%
|
8.89
+98.99%
|
4.47
|
| Operating Income |
|
-16.65
-21.20%
|
-13.74
-54.54%
|
-8.89
-98.99%
|
-4.47
|
| Total Operating Income As Reported |
|
-16.65
-21.20%
|
-13.74
-54.54%
|
-8.89
-98.99%
|
-4.47
|
| EBITDA |
|
-17.61
-66.64%
|
-10.57
+33.54%
|
-15.90
-263.62%
|
-4.37
|
| Normalized EBITDA |
|
-17.96
-10.26%
|
-16.29
-88.00%
|
-8.66
-98.15%
|
-4.37
|
| Reconciled Depreciation |
|
0.83
+45.20%
|
0.57
+31.12%
|
0.44
+364.89%
|
0.09
|
| EBIT |
|
-18.44
-65.53%
|
-11.14
+31.81%
|
-16.34
-265.75%
|
-4.47
|
| Total Unusual Items |
|
0.35
-93.85%
|
5.72
+179.08%
|
-7.24
|
—
|
| Total Unusual Items Excluding Goodwill |
|
0.35
-93.85%
|
5.72
+179.08%
|
-7.24
|
—
|
| Net Income |
|
-18.65
-67.06%
|
-11.16
+32.30%
|
-16.48
-221.91%
|
-5.12
|
| Pretax Income |
|
-18.65
-67.06%
|
-11.16
+32.30%
|
-16.48
-221.91%
|
-5.12
|
| Net Non Operating Interest Income Expense |
|
0.04
-81.39%
|
0.23
+257.14%
|
-0.15
+77.52%
|
-0.65
|
| Interest Expense Non Operating |
|
0.20
+920.00%
|
0.02
-86.39%
|
0.15
-77.52%
|
0.65
|
| Net Interest Income |
|
0.04
-81.39%
|
0.23
+257.14%
|
-0.15
+77.52%
|
-0.65
|
| Interest Expense |
|
0.20
+920.00%
|
0.02
-86.39%
|
0.15
-77.52%
|
0.65
|
| Interest Income Non Operating |
|
0.25
-1.59%
|
0.25
|
0.00
|
—
|
| Interest Income |
|
0.25
-1.59%
|
0.25
|
0.00
|
—
|
| Other Income Expense |
|
-2.04
-186.99%
|
2.35
+131.48%
|
-7.45
|
—
|
| Other Non Operating Income Expenses |
|
-2.39
+29.17%
|
-3.38
-1485.45%
|
-0.21
|
—
|
| Gain On Sale Of Security |
|
0.35
-93.85%
|
5.72
+179.08%
|
-7.24
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-18.65
-67.06%
|
-11.16
+32.30%
|
-16.48
-221.91%
|
-5.12
|
| Net Income From Continuing Operation Net Minority Interest |
|
-18.65
-67.06%
|
-11.16
+32.30%
|
-16.48
-221.91%
|
-5.12
|
| Net Income From Continuing And Discontinued Operation |
|
-18.65
-67.06%
|
-11.16
+32.30%
|
-16.48
-221.91%
|
-5.12
|
| Net Income Continuous Operations |
|
-18.65
-67.06%
|
-11.16
+32.30%
|
-16.48
-221.91%
|
-5.12
|
| Normalized Income |
|
-19.00
-12.53%
|
-16.88
-82.54%
|
-9.25
-80.61%
|
-5.12
|
| Net Income Common Stockholders |
|
-18.65
-67.06%
|
-11.16
+41.44%
|
-19.06
-272.15%
|
-5.12
|
| Otherunder Preferred Stock Dividend |
|
—
|
0.00
-100.00%
|
2.57
|
0.00
|
| Diluted EPS |
|
-0.42
+93.82%
|
-6.80
+42.06%
|
-11.74
-272.15%
|
-3.15
|
| Basic EPS |
|
-0.42
+93.82%
|
-6.80
+42.06%
|
-11.74
-272.15%
|
-3.15
|
| Basic Average Shares |
|
44.66
+2616.98%
|
1.64
+1.18%
|
1.62
+0.05%
|
1.62
|
| Diluted Average Shares |
|
44.66
+2616.98%
|
1.64
+1.18%
|
1.62
+0.05%
|
1.62
|
| Diluted NI Availto Com Stockholders |
|
-18.65
-67.06%
|
-11.16
+41.44%
|
-19.06
-272.15%
|
-5.12
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
9.62
-41.51%
|
16.45
+39.12%
|
11.82
+145.05%
|
4.82
|
| Current Assets |
|
6.35
-55.38%
|
14.23
+54.40%
|
9.21
+251.05%
|
2.62
|
| Cash Cash Equivalents And Short Term Investments |
|
4.89
-65.01%
|
13.98
+52.62%
|
9.16
+304.37%
|
2.27
|
| Cash And Cash Equivalents |
|
4.89
-65.01%
|
13.98
+52.62%
|
9.16
+304.37%
|
2.27
|
| Receivables |
|
—
|
—
|
0.00
-100.00%
|
0.30
|
| Loans Receivable |
|
—
|
—
|
0.00
-100.00%
|
0.30
|
| Prepaid Assets |
|
1.46
+546.67%
|
0.23
+525.00%
|
0.04
+24.14%
|
0.03
|
| Other Current Assets |
|
—
|
0.02
+12.50%
|
0.02
-46.67%
|
0.03
|
| Total Non Current Assets |
|
3.27
+47.50%
|
2.22
-14.93%
|
2.61
+18.51%
|
2.20
|
| Net PPE |
|
3.22
+45.33%
|
2.22
-14.93%
|
2.61
+18.51%
|
2.20
|
| Gross PPE |
|
3.67
+51.59%
|
2.42
-8.74%
|
2.65
+20.65%
|
2.20
|
| Accumulated Depreciation |
|
-0.45
-119.61%
|
-0.20
-334.04%
|
-0.05
|
0.00
|
| Machinery Furniture Equipment |
|
0.09
+95.74%
|
0.05
+67.86%
|
0.03
|
0.00
|
| Other Properties |
|
3.58
+50.72%
|
2.37
-9.56%
|
2.62
+19.37%
|
2.20
|
| Other Non Current Assets |
|
0.05
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
3.46
-74.74%
|
13.71
+29.73%
|
10.57
+19.82%
|
8.82
|
| Current Liabilities |
|
1.76
-86.18%
|
12.73
+38.58%
|
9.18
+29.83%
|
7.07
|
| Payables And Accrued Expenses |
|
0.94
-64.96%
|
2.70
+70.16%
|
1.58
+109.10%
|
0.76
|
| Payables |
|
0.94
-64.96%
|
2.70
+70.16%
|
1.58
+109.10%
|
0.76
|
| Accounts Payable |
|
0.94
-64.96%
|
2.70
+86.77%
|
1.44
+90.50%
|
0.76
|
| Other Payable |
|
—
|
—
|
0.14
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.71
-92.62%
|
9.57
+2543.37%
|
0.36
-93.73%
|
5.78
|
| Current Debt |
|
—
|
9.17
|
—
|
5.45
|
| Other Current Borrowings |
|
—
|
9.17
|
—
|
5.45
|
| Current Capital Lease Obligation |
|
0.71
+76.06%
|
0.40
+10.77%
|
0.36
+11.04%
|
0.33
|
| Other Current Liabilities |
|
0.11
-76.52%
|
0.46
-93.64%
|
7.24
+1244.98%
|
0.54
|
| Total Non Current Liabilities Net Minority Interest |
|
1.70
+73.17%
|
0.98
-28.95%
|
1.39
-20.72%
|
1.75
|
| Long Term Debt And Capital Lease Obligation |
|
1.70
+73.17%
|
0.98
-28.95%
|
1.39
-20.72%
|
1.75
|
| Long Term Capital Lease Obligation |
|
1.70
+73.17%
|
0.98
-28.95%
|
1.39
-20.72%
|
1.75
|
| Other Non Current Liabilities |
|
—
|
—
|
0.00
|
—
|
| Stockholders Equity |
|
6.16
+125.08%
|
2.73
+118.28%
|
1.25
+131.36%
|
-4.00
|
| Common Stock Equity |
|
6.16
+125.08%
|
2.73
+118.28%
|
1.25
+131.36%
|
-4.00
|
| Capital Stock |
|
0.00
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.00
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
3.33
+89.59%
|
1.75
+8.03%
|
1.62
+0.00%
|
1.62
|
| Ordinary Shares Number |
|
3.33
+89.59%
|
1.75
+8.03%
|
1.62
+0.00%
|
1.62
|
| Additional Paid In Capital |
|
60.32
+57.68%
|
38.25
+49.37%
|
25.61
+960.85%
|
2.41
|
| Retained Earnings |
|
-54.16
-52.50%
|
-35.52
-45.82%
|
-24.36
-209.41%
|
-7.87
|
| Total Equity Gross Minority Interest |
|
6.16
+125.08%
|
2.73
+118.28%
|
1.25
+131.36%
|
-4.00
|
| Total Capitalization |
|
6.16
+125.08%
|
2.73
+118.28%
|
1.25
+131.36%
|
-4.00
|
| Working Capital |
|
4.59
+205.59%
|
1.50
+4593.75%
|
0.03
+100.72%
|
-4.45
|
| Invested Capital |
|
6.16
-48.28%
|
11.90
+849.96%
|
1.25
-13.88%
|
1.46
|
| Total Debt |
|
2.41
-77.16%
|
10.55
+504.06%
|
1.75
-76.78%
|
7.52
|
| Net Debt |
|
—
|
—
|
—
|
3.19
|
| Capital Lease Obligations |
|
2.41
+74.01%
|
1.39
-20.72%
|
1.75
-15.73%
|
2.07
|
| Net Tangible Assets |
|
6.16
+125.08%
|
2.73
+118.28%
|
1.25
+131.36%
|
-4.00
|
| Tangible Book Value |
|
6.16
+125.08%
|
2.73
+118.28%
|
1.25
+131.36%
|
-4.00
|
| Dueto Related Parties Current |
|
—
|
0.00
-100.00%
|
0.14
|
0.00
|
| Other Equity Interest |
|
—
|
—
|
—
|
1.46
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-16.39
-37.75%
|
-11.90
-85.92%
|
-6.40
-57.43%
|
-4.07
|
| Cash Flow From Continuing Operating Activities |
|
-16.39
-37.75%
|
-11.90
-85.92%
|
-6.40
-57.43%
|
-4.07
|
| Net Income From Continuing Operations |
|
-18.65
-67.06%
|
-11.16
+32.30%
|
-16.48
-221.91%
|
-5.12
|
| Depreciation Amortization Depletion |
|
0.83
+45.20%
|
0.57
+31.12%
|
0.44
+364.89%
|
0.09
|
| Depreciation |
|
0.83
+45.20%
|
0.57
+31.12%
|
0.44
+364.89%
|
0.09
|
| Depreciation And Amortization |
|
0.83
+45.20%
|
0.57
+31.12%
|
0.44
+364.89%
|
0.09
|
| Other Non Cash Items |
|
—
|
1.86
+2200.00%
|
0.08
-79.18%
|
0.39
|
| Stock Based Compensation |
|
2.69
+21.05%
|
2.22
+25.72%
|
1.76
+566.04%
|
0.27
|
| Operating Gains Losses |
|
0.27
+104.77%
|
-5.72
-178.30%
|
7.31
|
—
|
| Gain Loss On Investment Securities |
|
-0.35
+93.85%
|
-5.72
-178.30%
|
7.31
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
1.77
+864.22%
|
-0.23
|
0.00
|
—
|
| Change In Working Capital |
|
-3.31
-692.49%
|
0.56
+13.39%
|
0.49
+60.59%
|
0.31
|
| Change In Prepaid Assets |
|
-1.23
-550.79%
|
-0.19
-2600.00%
|
-0.01
-187.50%
|
0.01
|
| Change In Payables And Accrued Expense |
|
-1.50
-235.07%
|
1.11
+36.95%
|
0.81
+54.67%
|
0.53
|
| Change In Payable |
|
-1.50
-235.07%
|
1.11
+36.95%
|
0.81
+54.67%
|
0.53
|
| Change In Account Payable |
|
-1.50
-219.87%
|
1.25
+86.74%
|
0.67
+27.81%
|
0.53
|
| Change In Other Current Assets |
|
-0.03
-1400.00%
|
-0.00
-114.29%
|
0.01
+333.33%
|
-0.01
|
| Change In Other Current Liabilities |
|
-0.55
-51.93%
|
-0.36
-11.04%
|
-0.33
-48.18%
|
-0.22
|
| Investing Cash Flow |
|
-0.26
-42.39%
|
-0.18
+62.83%
|
-0.49
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-0.26
-42.39%
|
-0.18
+62.83%
|
-0.49
|
0.00
|
| Net PPE Purchase And Sale |
|
-0.26
-42.39%
|
-0.18
+62.83%
|
-0.49
|
0.00
|
| Purchase Of PPE |
|
-0.26
-42.39%
|
-0.18
+62.83%
|
-0.49
|
0.00
|
| Capital Expenditure |
|
-0.26
-42.39%
|
-0.18
+62.83%
|
-0.49
|
—
|
| Financing Cash Flow |
|
7.57
-55.26%
|
16.91
+22.58%
|
13.79
+132.79%
|
5.92
|
| Cash Flow From Continuing Financing Activities |
|
7.57
-55.26%
|
16.91
+22.58%
|
13.79
+132.79%
|
5.92
|
| Net Issuance Payments Of Debt |
|
0.97
-89.63%
|
9.40
+3033.33%
|
0.30
-92.05%
|
3.77
|
| Issuance Of Debt |
|
4.38
-53.46%
|
9.40
+3033.33%
|
0.30
-93.02%
|
4.30
|
| Repayment Of Debt |
|
-3.40
|
0.00
|
0.00
+100.00%
|
-0.53
|
| Short Term Debt Issuance |
|
4.38
-53.46%
|
9.40
+3033.33%
|
0.30
-93.02%
|
4.30
|
| Short Term Debt Payments |
|
-3.40
|
0.00
|
0.00
+100.00%
|
-0.53
|
| Net Short Term Debt Issuance |
|
0.97
-89.63%
|
9.40
+3033.33%
|
0.30
-92.05%
|
3.77
|
| Net Common Stock Issuance |
|
6.59
-12.22%
|
7.51
|
0.00
|
—
|
| Net Other Financing Charges |
|
—
|
—
|
-2.65
|
—
|
| Changes In Cash |
|
-9.09
-288.53%
|
4.82
-30.09%
|
6.90
+271.01%
|
1.86
|
| Beginning Cash Position |
|
13.98
+52.62%
|
9.16
+304.37%
|
2.27
+456.76%
|
0.41
|
| End Cash Position |
|
4.89
-65.01%
|
13.98
+52.62%
|
9.16
+304.37%
|
2.27
|
| Free Cash Flow |
|
-16.66
-37.82%
|
-12.09
-75.25%
|
-6.90
-69.60%
|
-4.07
|
| Interest Paid Supplemental Data |
|
0.20
+920.00%
|
0.02
+900.00%
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
6.59
-12.22%
|
7.51
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
6.59
-12.22%
|
7.51
-53.48%
|
16.14
+650.60%
|
2.15
|
| Net Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
16.14
+650.60%
|
2.15
|
| Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
16.14
+650.60%
|
2.15
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-20 View
- 8-K2026-04-17 View
- 8-K2026-04-09 View
- 8-K2026-04-03 View
- 8-K2026-04-02 View
- 8-K2026-03-06 View
- 42026-03-05 View
- 42026-03-04 View
- 42026-03-03 View
- 42026-03-02 View
- 10-K2026-02-24 View
- 8-K2026-02-23 View
- 8-K2026-02-06 View
- 8-K2026-01-02 View
- 8-K2025-12-15 View
- 42025-12-12 View
- 8-K2025-11-25 View
- 8-K2025-11-19 View
- 10-Q2025-10-31 View
- 8-K2025-08-08 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|